Abeona Therapeutics Inc (NASDAQ:ABEO) Director Faith L. Charles Buys 7,550 Shares

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Faith L. Charles bought 7,550 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were acquired at an average price of $3.28 per share, with a total value of $24,764.00. Following the purchase, the director now owns 78,323 shares in the company, valued at $256,899.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Abeona Therapeutics Trading Up 5.5 %

Shares of ABEO stock opened at $3.44 on Tuesday. The stock has a 50 day moving average of $7.23 and a two-hundred day moving average of $5.62. Abeona Therapeutics Inc has a 12 month low of $2.83 and a 12 month high of $9.01. The company has a market capitalization of $94.10 million, a P/E ratio of -1.33 and a beta of 1.49.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.13). Sell-side analysts predict that Abeona Therapeutics Inc will post -2.05 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

A number of hedge funds have recently modified their holdings of ABEO. Simplex Trading LLC lifted its position in shares of Abeona Therapeutics by 1,889.9% in the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 13,418 shares during the period. Jump Financial LLC bought a new stake in shares of Abeona Therapeutics in the 4th quarter worth approximately $199,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth approximately $648,000. Worth Venture Partners LLC lifted its position in shares of Abeona Therapeutics by 76.6% in the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after acquiring an additional 121,969 shares during the period. Finally, Barclays PLC lifted its position in shares of Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after acquiring an additional 185,638 shares during the period. Institutional investors own 80.56% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on ABEO shares. StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $36.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, April 23rd.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.